Bioinorganic Chemistry of Platinum(IV) Complexes as Platforms for Anticancer Agents

Author(s): Little Nagyal, Amit Kumar, Rishipal Sharma, Rohit Yadav, Pratibha Chaudhary, Rajeev Singh*

Journal Name: Current Bioactive Compounds

Volume 16 , Issue 6 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The current review focuses on the comprehensive studies of platinum-based complexes that are known to exhibit anticancer properties. The research on metal-particle work has helped in treating sicknesses which plays an imperative part in therapeutic bioinorganic science. Understanding the biochemistry of the detoxification mechanism of metals can help in advancing as well as enhancing the anticancer property of metal complexes for several types of a tumour. The classifications of complexes discussed have been done on the basis of Platinum oxidation states and binding sites of the ligands. Further background and current status of Pt(IV) complexes are briefly explained along with a special reference to Structural Activity Relationships and Mode of Action. The coordination chemistry of Pt(IV) has been summarised and Pt(IV) complexes are reviewed on the basis of binding of Pt(IV) with Human Serum Albumin and DNA. Finally, the results were summarized and concluded emphasizing on the most important features.

Keywords: Platinum complexes, anticancer, structural activity relationships, human serum albumin, DNA, chemotherapy.

[1]
Kostawa, I. Platinum complexes as anticancer agents Recent Pat. Anti-cancer Drug Discov., 2006, 1, 1-22.
[2]
Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry. Introduction. Chem. Rev., 1999, 99(9), 2201-2204.
[http://dx.doi.org/10.1021/cr980419w] [PMID: 11749478]
[3]
Sakurai, H.; Kojima, Y.; Yoshikawa, Y.; Kawabe, K.; Yasui, H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev., 2002, 226, 187-198.
[http://dx.doi.org/10.1016/S0010-8545(01)00447-7]
[4]
Ali, H.; van Lier, J.E. Metal complexes as photo- and radiosensitizers. Chem. Rev., 1999, 99(9), 2379-2450.
[http://dx.doi.org/10.1021/cr980439y] [PMID: 11749485]
[5]
Louie, A.Y.; Meade, T.J. Metal complexes as enzyme inhibitors. Chem. Rev., 1999, 99(9), 2711-2734.
[http://dx.doi.org/10.1021/cr9804285] [PMID: 11749498]
[6]
Volkert, W.A.; Hoffman, T.J. Therapeutic radiopharmaceuticals. Chem. Rev., 1999, 99(9), 2269-2292.
[http://dx.doi.org/10.1021/cr9804386] [PMID: 11749482]
[7]
Kumar, R.; Singh, R. Chromium(III) complexes with different chromospheres macrocyclic ligands: Synthesis and spectroscopic studies. Turk. J. Chem., 2006, 30, 77-87.
[8]
Eastman, A. Cisplatin: Chemistry and Biochemistry of a Lead-ing Anticancer Drug, 1st ed; Wiley-VCH: Weinheim, 1999.
[9]
Daniel, K.G.; Chen, D.; Orlu, S.; Cui, Q.C.; Miller, F.R.; Dou, Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res., 2005, 7(6), R897-R908.
[http://dx.doi.org/10.1186/bcr1322] [PMID: 16280039]
[10]
Cvek, B.; Milacic, V.; Taraba, J.; Dou, Q.P. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J. Med. Chem., 2008, 51(20), 6256-6258.
[http://dx.doi.org/10.1021/jm8007807] [PMID: 18816109]
[11]
Daniel, K.G.; Gupta, P.; Harbach, R.H.; Guida, W.C.; Dou, Q.P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem. Pharmacol., 2004, 67(6), 1139-1151.
[http://dx.doi.org/10.1016/j.bcp.2003.10.031] [PMID: 15006550]
[12]
Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des., 2010, 16(16), 1813-1825.
[http://dx.doi.org/10.2174/138161210791209009] [PMID: 20337575]
[13]
Weiss, R.B.; Christian, M.C. New cisplatin analogues in development. A review. Drugs, 1993, 46(3), 360-377.
[http://dx.doi.org/10.2165/00003495-199346030-00003] [PMID: 7693428]
[14]
Criado, J.J.; Manzano, J.L.; Rodríguez-Fernández, E. New organotropic compounds. Synthesis, characterization and reactivity of Pt(II) and Au(III) complexes with bile acids: DNA interactions and ‘in vitro’ anticancer activity. J. Inorg. Biochem., 2003, 96(2-3), 311-320.
[http://dx.doi.org/10.1016/S0162-0134(03)00240-X] [PMID: 12888266]
[15]
Wong, E.; Giandomenico, C.M. Current status of platinum-based antitumor drugs. Chem. Rev., 1999, 99(9), 2451-2466.
[http://dx.doi.org/10.1021/cr980420v] [PMID: 11749486]
[16]
Galanski, M.; Jakupec, M.A.; Keppler, B.K. Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches. Curr. Med. Chem., 2005, 12(18), 2075-2094.
[http://dx.doi.org/10.2174/0929867054637626] [PMID: 16101495]
[17]
Johnstone, T.C.; Park, G.Y.; Lippard, S.J. Understanding and improving platinum anticancer drugs-phenanthriplatin. Anticancer Res., 2014, 34(1), 471-476.
[PMID: 24403503]
[18]
Choy, H.; Park, C.; Yao, M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin. Cancer Res., 2008, 14(6), 1633-1638.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-2176] [PMID: 18347164]
[19]
McDonald, D.; Hunt, L.B. A History of Platinum and its Allied metals, 1st ed; Europa Publications Limited: England, 1982, pp. 1-11.
[20]
(a)Mollica, A.; Costante, R.; Fiorito, S.; Genovese, S.; Stefanucci, A.; Mathieu, V.; Kiss, R.; Epifano, F. Synthesis and anti-cancer activity of naturally occurring 2,5-diketopiperazines. Fitoterapia, 2014, 98, 91-97.
[http://dx.doi.org/10.1016/j.fitote.2014.07.010] [PMID: 25064216]
(b)Mollica, A.; Stefanucci, A.; Feliciani, F.; Cacciatore, I.; Cornacchia, C.; Pinnen, F. Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer. Curr. Drug Deliv., 2012, 9(2), 122-131.
[http://dx.doi.org/10.2174/156720112800234558] [PMID: 22283650]
(c)Mollica, A.; Costante, R.; Stefanucci, A.; Novellino, E. new insight on the synthesis of neurotoxins domoic acid and kainic acid. Protein Pept. Lett., 2015, 22(8), 696-711.
[http://dx.doi.org/10.2174/0929866522666150206170716] [PMID: 25658114]
[21]
(a)Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
[http://dx.doi.org/10.1038/nrc2167] [PMID: 17625587]
(b)Jamieson, E.R.; Lippard, S.J. Structure, recognition, and processing of cisplatin− DNA adducts. Chem. Rev., 1999, 99(9), 2467-2498.
[http://dx.doi.org/10.1021/cr980421n] [PMID: 11749487]
[22]
Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 2005, 4(4), 307-320.
[http://dx.doi.org/10.1038/nrd1691] [PMID: 15789122]
[23]
Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22(47), 7265-7279.
[http://dx.doi.org/10.1038/sj.onc.1206933] [PMID: 14576837]
[24]
Barefoot, R.R. Speciation of platinum compounds: A review of recent applications in studies of platinum anticancer drugs. J. Chromatogr. B Biomed. Sci. Appl., 2001, 751(2), 205-211.
[http://dx.doi.org/10.1016/S0378-4347(00)00498-9] [PMID: 11236075]
[25]
Einhorn, L.H. Treatment of testicular cancer: A new and improved model. J. Clin. Oncol., 1990, 8(11), 1777-1781.
[http://dx.doi.org/10.1200/JCO.1990.8.11.1777] [PMID: 1700077]
[26]
Yoshida, M.; Khokhar, A.R.; Siddik, Z.H.; Siddik, Z.H. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). Cancer Res., 1994, 54(17), 4691-4697.
[PMID: 8062266]
[27]
Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The next generation of platinum drugs: Targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem. Rev., 2016, 116(5), 3436-3486.
[http://dx.doi.org/10.1021/acs.chemrev.5b00597] [PMID: 26865551]
[28]
Harrap, K.R. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev., 1985, 12(Suppl. A), 21-33.
[http://dx.doi.org/10.1016/0305-7372(85)90015-5] [PMID: 3910219]
[29]
Apps, M.G.; Choi, E.H.Y.; Wheate, N.J. The state-of-play and future of platinum drugs. Endocr. Relat. Cancer, 2015, 22(4), R219-R233.
[http://dx.doi.org/10.1530/ERC-15-0237] [PMID: 26113607]
[30]
Saif, M.W. Hypersensitivity reactions associated with oxaliplatin. Expert Opin. Drug Saf., 2006, 5(5), 687-694.
[http://dx.doi.org/10.1517/14740338.5.5.687] [PMID: 16907658]
[31]
Shimada, M.; Itamochi, H.; Kigawa, J. Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag. Res., 2013, 5, 67-76.
[http://dx.doi.org/10.2147/CMAR.S35785] [PMID: 23696716]
[32]
Alberts, D.S.; Dorr, R.T. New perspectives on an old friend: Optimizing carboplatin for the treatment of solid tumors. Oncologist, 1998, 3(1), 15-34.
[http://dx.doi.org/10.1634/theoncologist.3-1-15] [PMID: 10388081]
[33]
Ahn, J.H.; Kang, Y.K.; Kim, T.W.; Bahng, H.; Chang, H.M.; Kang, W.C.; Kim, W.K.; Lee, J.S.; Park, J.S. Nephrotoxicity of heptaplatin: A randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother. Pharmacol., 2002, 50(2), 104-110.
[http://dx.doi.org/10.1007/s00280-002-0483-x] [PMID: 12172973]
[34]
Natile, G.; Coluccia, M. Current status of trans-platinum compounds in cancer therapy. Coord. Chem. Rev., 2001, 216, 383-410.
[http://dx.doi.org/10.1016/S0010-8545(01)00315-0]
[35]
Wyrick, S.D.; Chaney, S.J. Synthesis of [195mPt]‐tetraplatin. J. Labelled Comp. Radiopharm., 1990, 28, 753-756.
[http://dx.doi.org/10.1002/jlcr.2580280703]
[36]
Sessa, C.; Vermorken, J.; Renard, J.; Kaye, S.; Smith, D.; ten Bokkel Huinink, W.; Cavalli, F.; Pinedo, H. Phase II study of iproplatin in advanced ovarian carcinoma. J. Clin. Oncol., 1988, 6(1), 98-105.
[http://dx.doi.org/10.1200/JCO.1988.6.1.98] [PMID: 3335895]
[37]
Clavel, M.; Monfardini, S.; Gundersen, S.; Kaye, S.; Siegenthaler, P.; Renard, J.; van Glabbeke, M.; Pinedo, H.M. Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy. Eur. J. Cancer Clin. Oncol., 1988, 24(8), 1345-1348.
[http://dx.doi.org/10.1016/0277-5379(88)90226-X] [PMID: 3181255]
[38]
Petrelli, N.J.; Creaven, P.J.; Herrera, L.; Mittelman, A. Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. Cancer Chemother. Pharmacol., 1989, 23(1), 61-62.
[http://dx.doi.org/10.1007/BF00258461] [PMID: 2909291]
[39]
Neidle, S.; Snook, C.F.; Murrer, B.A.; Barnard, C.F.J. Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV), an orally active anticancer drug. Acta Crystallogr. C, 1995, 51(Pt 5), 822-824.
[http://dx.doi.org/10.1107/S0108270194013600] [PMID: 7779322]
[40]
Bhargava, A.; Vaishampayan, U.N. Satraplatin: Leading the new generation of oral platinum agents. Expert Opin. Investig. Drugs, 2009, 18(11), 1787-1797.
[http://dx.doi.org/10.1517/13543780903362437] [PMID: 19888874]
[41]
Sonpavde, G.; Sternberg, C.N. Satraplatin for the therapy of castration-resistant prostate cancer. Future Oncol., 2009, 5(7), 931-940.
[http://dx.doi.org/10.2217/fon.09.84] [PMID: 19792961]
[42]
Kelland, L.R.; Murrer, B.A.; Abel, G.; Giandomenico, C.M.; Mistry, P.; Harrap, K.R. Ammine/amine platinum(IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 1992, 52(4), 822-828.
[PMID: 1737343]
[43]
Fischer, J.; Ganellin, C.R. Analogue-based Drug Discovery II, 2nd ed; Wiley VCH: Weinheim, 2006, pp. 3-520.
[http://dx.doi.org/10.1002/3527608001]
[44]
Pasqua, A.J.D.; Goodisman, J.; Kerwood, D.J.; Toms, B.B.; Dubowy, R.L.; Dabrowiak, J.C. Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocy-anates. Chem. Res. Toxicol., 2007, 20, 896-904.
[PMID: 17497898]
[45]
Di Pasqua, A.J.; Goodisman, J.; Kerwood, D.J.; Toms, B.B.; Dubowy, R.L.; Dabrowiak, J.C. Activation of carboplatin by carbonate. Chem. Res. Toxicol., 2006, 19(1), 139-149.
[http://dx.doi.org/10.1021/tx050261s] [PMID: 16411667]
[46]
de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000, 18(16), 2938-2947.
[http://dx.doi.org/10.1200/JCO.2000.18.16.2938] [PMID: 10944126]
[47]
Graham, J.; Mushin, M.; Kirkpatrick, P. Oxaliplatin. Nat. Rev. Drug Discov., 2004, 3(1), 11-12.
[http://dx.doi.org/10.1038/nrd1287] [PMID: 14756144]
[48]
Chay, W.Y.; Chew, L.; Yeoh, T.T.; Tan, M.H. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: Case series analysis. Acta Oncol., 2010, 49, 515-517.
[http://dx.doi.org/10.3109/02841860903464015] [PMID: 20092386]
[49]
Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer, 1998, 34(10), 1522-1534.
[http://dx.doi.org/10.1016/S0959-8049(98)00224-X] [PMID: 9893623]
[50]
Pinzani, V.; Bressolle, F.; Haug, I.J.; Galtier, M.; Blayac, J.P.; Balmès, P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review. Cancer Chemother. Pharmacol., 1994, 35(1), 1-9.
[http://dx.doi.org/10.1007/BF00686277] [PMID: 7987972]
[51]
Moncharmont, C.; Auberdiac, P.; Mélis, A.; Afqir, S.; Pacaut, C.; Chargari, C.; Merrouche, Y.; Magné, N. Cisplatin or carboplatin, that is the question. Bull. Cancer, 2011, 98(2), 164-175.
[http://dx.doi.org/10.1684/bdc.2011.1307] [PMID: 21382796]
[52]
Hall, M.D.; Hambley, T.W. Platinum (IV) antitumour compounds: Their bioinorganic chemistry. Coord. Chem. Rev., 2002, 232, 49-67.
[http://dx.doi.org/10.1016/S0010-8545(02)00026-7]
[53]
Montaña, A.M.; Batalla, C.; Batalla, C. The rational design of anticancer platinum complexes: The importance of the structure-activity relationship. Curr. Med. Chem., 2009, 16(18), 2235-2260.
[http://dx.doi.org/10.2174/092986709788453087] [PMID: 19519389]
[54]
Raynaud, F.I.; Odell, D.E.; Kelland, L.R. Intracellular metabolism of the orally active platinum drug JM216: Influence of glutathione levels. Br. J. Cancer, 1996, 74(3), 380-386.
[http://dx.doi.org/10.1038/bjc.1996.369] [PMID: 8695352]
[55]
Raynaud, F.I.; Boxall, F.E.; Goddard, P.; Barnard, C.F.J.; Murrer, B.A.; Kelland, L.R. Development of an orally active platinum anticancer drug: JM216. Anticancer Res., 1997, 16, 1857.
[PMID: 8712713]
[56]
Raynaud, F.I.; Mistry, P.; Donaghue, A.; Poon, G.K.; Kelland, L.R.; Barnard, C.F.J.; Murrer, B.A.; Harrap, K.R. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother. Pharmacol., 1996, 38(2), 155-162.
[http://dx.doi.org/10.1007/s002800050464] [PMID: 8616906]
[57]
Neidle, S.; Murrer, B.A.; Barnard, C.F.J. Conformational flex-ibility and its potential influence on metabolic reactions for the anti-tumour compound a-ammine-bd-bis(butyrato)-cf-dichloro-e-cyclohexylamine platinum(IV). Bioorg. Med. Chem., 1996, 6, 421.
[http://dx.doi.org/10.1016/0960-894X(96)00046-7]
[58]
Carr, J.L.; Tingle, M.D.; McKeage, M.J. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol., 2002, 50(1), 9-15.
[http://dx.doi.org/10.1007/s00280-002-0462-2] [PMID: 12111106]
[59]
Kurata, T.; Tamura, T.; Sasaki, Y.; Fujii, H.; Negoro, S.; Fu-kuoka, M.; Saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. J. Clin. Oncol., 2002, 30, 377-384.
[60]
Christian, M.C. Seventh International Symposium on Platinum and other Metal Coordination Compounds in Cancer Chemotherapy, 1995, p. 128.
[61]
Anderson, H.J.; Wagstaff, D.; Crowther, R.; Swindell, M.; Lind, J.; McGregor, M.; Timms, S.; Brown, D.; Palmer, P. The status of platinum anticancer drugs in the clinic and in clinical trials. Eur. J. Cancer Clin. Oncol., 1988, 24, 1471-1479.
[http://dx.doi.org/10.1016/0277-5379(88)90338-0] [PMID: 3053207]
[62]
Paolozzi, F.P.; Gaver, R.; Poiesz, B.J.; Louie, A.; DiFino, S.; Comis, R.L.; Newman, N.; Ginsberg, S. Phase I-preliminary phase II trial of iproplatin, a cisplatin analogue. Invest. New Drugs, 1988, 6(3), 199-206.
[http://dx.doi.org/10.1007/BF00175398] [PMID: 3192385]
[63]
Chaney, S.G.; Wyrick, S.; Till, G.K. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. Cancer Res., 1990, 50(15), 4539-4545.
[PMID: 2196115]
[64]
Mellis, K.J.; Barnard, C.F.J.; Murrer, B.A.; Kelland, L.R. In vitro circumvention of cisplatin resistance by the novel steri-cally hindered platinum complex AMD473. Int. J. Cancer, 1995, 62, 717.
[65]
Kozubík, A.; Vaculová, A.; Soucek, K.; Vondrácek, J.; Turánek, J.; Hofmanová, J. Novel anticancer platinum(IV) complexes with adamantylamine: Their efficiency and innovative chemotherapy strategies modifying lipid metabolism. Met. Based Drugs, 2008.2008417897
[http://dx.doi.org/10.1155/2008/417897] [PMID: 18414587]
[66]
Choi, S.; Filotto, C.; Bisanzo, M.; Delaney, S.; Lagasee, D.; Whitworth, J.L.; Jusko, A.; Wood, N.A.; Willingham, J.; Schwenker, A. Reduction and anticancer activity of plati-num(IV). Complexes. Inorg. Chem, 1998, 37, 2500.
[http://dx.doi.org/10.1021/ic971047x]
[67]
Elding, L.I.; Gustafson, L. Bromide anation kinetics for some platinum(IV) bromo aqua complexes. Inorg. Chim. Acta, 1977, 22, 201.
[http://dx.doi.org/10.1016/S0020-1693(00)90919-8]
[68]
Drougge, L.I.; Elding, L. Platinum(IV) antitumour compounds: Their bioinorganic chemistry. Inorg. Chem. Acta, 2006, 175, 22.
[69]
Giandomenico, C.M.; Abrams, M.J.; Murrer, B.A.; Vollano, J.F.; Rheinheimer, M.I.; Wyer, S.B.; Bossard, G.E.; Higgins, J.D. Carboxylation of kinetically inert Platinum(IV) hydroxy complexes. An entr.acte.ee into orally active Platinum(IV) antitumor agents. Inorg. Chem., 1995, 34(5), 1015-1021.
[http://dx.doi.org/10.1021/ic00109a004] [PMID: 20000850]
[70]
Gibbons, G.R.; Wyrick, S.; Chaney, S.G. An unexpected biotransformation pathway for tetrachloro. Cancer Res., 1989, 49, 1402.
[PMID: 2924297]
[71]
Pendyala, L.; Arakali, A.V.; Sansone, P.; Cowens, J.W.; Creaven, P.J. DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II). Cancer Chemother. Pharmacol., 1990, 27(3), 248-250.
[http://dx.doi.org/10.1007/BF00685722] [PMID: 2265462]
[72]
Chaney, S.G.; Gibbons, G.R.; Wyrick, S.D.; Podhasky, P. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Res., 1991, 51(3), 969-973.
[PMID: 1988140]
[73]
Wilson, J.J.; Lippard, S.J. Synthetic methods for the preparation of platinum anticancer complexes. Chem. Rev., 2014, 114(8), 4470-4495.
[http://dx.doi.org/10.1021/cr4004314] [PMID: 24283498]
[74]
Shi, T.; Rabenstein, D.L. Discovery of a highly selective and efficient reagent for formation of intramolecular disulfide bonds in peptides. J. Am. Chem. Soc., 2000, 122, 6809.
[http://dx.doi.org/10.1021/ja0008618]
[75]
Varbanov, H.P.; Jakupec, M.A.; Jensen, A.R.F.; Galanski, M.; Keppler, B.K. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. J. Med. Chem., 2013, 56, 330-344.
[http://dx.doi.org/10.1021/jm3016427] [PMID: 23214999]
[76]
Hall, M.D.; Mellor, H.R.; Callaghan, R.; Hambley, T.W. Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem., 2007, 50(15), 3403-3411.
[http://dx.doi.org/10.1021/jm070280u] [PMID: 17602547]
[77]
Wexselblatt, E.; Gibson, D. Encapsulation of Pt(IV) prodrugs within a Pt(II) cage for drug delivery. J. Inorg. Biochem., 2007, 117, 220-229.
[http://dx.doi.org/10.1016/j.jinorgbio.2012.06.013] [PMID: 22877926]
[78]
Sinisi, M.; Intini, F.P.; Natile, G. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent. Inorg. Chem., 2012, 51(18), 9694-9704.
[http://dx.doi.org/10.1021/ic300957v] [PMID: 22921246]
[79]
Talman, E.G.; Kidani, Y.; Mohrmann, L. Comprehensive coordination chemistry II: From biology to nanotechnology. J. Inorg. Chim. Acta, 1998, 283, 251.
[http://dx.doi.org/10.1016/S0020-1693(98)00311-9]
[80]
Hambley, T.W.; Battle, A.R.; Deacon, G.B.; Lawrenz, E.T.; Fallon, G.D.; Gatehouse, B.M.; Webster, L.K.; Rainone, S. Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness. J. Inorg. Biochem., 1999, 77(1-2), 3-12.
[http://dx.doi.org/10.1016/S0162-0134(99)00133-6] [PMID: 10626347]
[81]
Battle, A.R. Interrelationships between electrochemistry, struc-ture and activity of platinum(IV) complexes; School of Chemistry, Faculty of Science, University of Sydney, 2001.
[82]
Kratochwil, N.A.; Ivanov, A.I.; Patriarca, M.; Parkinson, J.A.; Gouldsworthy, A.M.; Murdoch, P.D.; Sadler, P.J. Comprehensive coordination chemistry II: From biology to nanotechnology. J. Am. Chem. Soc., 1999, 121, 8193.
[http://dx.doi.org/10.1021/ja990768n]
[83]
Braddock, P.D.; Connors, T.A.; Jones, M.; Khokhar, A.R.; Melzack, D.H.; Tobe, M.L. Structure and activity relationships of platinum complexes with anti-tumour activity. Chem. Biol. Interact., 1975, 11(3), 145-161.
[http://dx.doi.org/10.1016/0009-2797(75)90095-2] [PMID: 1157188]
[84]
Cleare, M.J. Progress in nucleic acid research and molecular biology. J. Hematol. Oncol., 1977, 7, 1.
[85]
Kratochwil, N.A.; Bednarski, P.J. Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro and cis-diiodo-Pt(IV)-ethylenediamines. Arch. Pharm. (Weinheim), 1999, 332(8), 279-285.
[http://dx.doi.org/10.1002/(SICI)1521-4184(19998)332:8<279::AID-ARDP279>3.0.CO;2-1] [PMID: 10489538]
[86]
van de Waterbeemd, H.; Smith, D.A.; Jones, B.C.J. Lipophilicity in PK design: Methyl, ethyl, futile. J. Comput. Aided Mol. Des., 2001, 15(3), 273-286.
[http://dx.doi.org/10.1023/A:1008192010023] [PMID: 11289080]
[87]
Rabenstein, D.L.; Theriault, Y.A. A nuclear magnetic resonance study of the kinetics and equilibria for the oxidation of penicillamine and N-acetylpenicillamine by glutathione disulphide. Can. J. Chem., 1984, 62, 1672-1680.
[http://dx.doi.org/10.1139/v84-287]
[88]
Leo, A.; Hansch, C.; Elkins, D. Partition coefficients and their uses. Chem. Rev., 1971, 71, 525-616.
[http://dx.doi.org/10.1021/cr60274a001]
[89]
Platts, J.A.; Hibbs, D.A.; Hambley, T.W.; Hall, M.D. Synthesis, characterization, and cytotoxicity of Platinum(IV) carbamate complexes. J. Med. Chem., 2001, 44, 472.
[http://dx.doi.org/10.1021/jm001080k] [PMID: 11462986]
[90]
McKeage, M.J.; Higgins, J.D., III; Kelland, L.R. Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991. Br. J. Cancer, 1991, 64(4), 788-792.
[http://dx.doi.org/10.1038/bjc.1991.400] [PMID: 1911229]
[91]
Oldfield, S.P.; Hall, M.D.; Platts, J.A. Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake. J. Med. Chem., 2007, 50(21), 5227-5237.
[http://dx.doi.org/10.1021/jm0708275] [PMID: 17900102]
[92]
Kvardova, V.; Hrstka, R.; Walerych, D.; Muller, P.; Matoulkova, E.; Hruskova, V.; Stelclova, D.; Sova, P.; Vojtesek, B. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol. Cancer, 2010, 9, 147.
[http://dx.doi.org/10.1186/1476-4598-9-147] [PMID: 20550649]
[93]
Mistry, P.; Kelland, L.R.; Loh, S.Y.; Abel, G.; Murrer, B.A.; Harrap, K.R. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res., 1992, 52(22), 6188-6193.
[PMID: 1423261]
[94]
Eastman, A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem. Pharmacol., 1987, 36(23), 4177-4178.
[http://dx.doi.org/10.1016/0006-2952(87)90581-8] [PMID: 3689445]
[95]
Ang, W.H.; Pilet, S.; Scopelliti, R.; Bussy, F.; Juillerat-Jeanneret, L.; Dyson, P.J. Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J. Med. Chem., 2005, 48(25), 8060-8069.
[http://dx.doi.org/10.1021/jm0506468] [PMID: 16335930]
[96]
Poon, G.K.; Mistry, P.; Raynaud, F.I.; Harrap, K.R.; Murrer, B.A.; Barnard, C.F.J. Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates. J. Pharm. Biomed. Anal., 1995, 13(12), 1493-1498.
[http://dx.doi.org/10.1016/0731-7085(95)01571-X] [PMID: 8788134]
[97]
Yap, S.Q.; Chin, C.F.; Hong Thng, A.H.; Pang, Y.Y.; Ho, H.K.; Ang, W.H. Finely tuned asymmetric Platinum(IV) anticancer complexes: Structure-activity relationship and application as orally available prodrugs. ChemMedChem, 2017, 12(4), 300-311.
[http://dx.doi.org/10.1002/cmdc.201600577] [PMID: 28028938]
[98]
Sugii, A.; Nishimura, K.; Harada, K.; Nakayama, M. High performancec liquid chromatography of bovine serum albumin-cis-diaminedichloroplatinum (II) complexes on N-Methylpyridinium polymer column. S. Chem. Pharm. Bull, 1991, 39, 408.
[http://dx.doi.org/10.1248/cpb.39.408]
[99]
Esposito, B.P.; Najjar, R. Interactions of antitumoral platinum-group metallodrugs with albumin. Coord. Chem. Rev., 2002, 232, 137-149.
[http://dx.doi.org/10.1016/S0010-8545(02)00049-8]
[100]
Varbanov, H.; Valiahdi, S.M.; Legin, A.A.; Jakupec, M.A.; Roller, A.; Galanski, M.; Keppler, B.K. Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. Eur. J. Med. Chem., 2011, 46(11), 5456-5464.
[http://dx.doi.org/10.1016/j.ejmech.2011.09.006] [PMID: 21940073]
[101]
Bolli, A.; Marino, M.; Rimbach, G.; Fanali, G.; Fasano, M.; Ascenzi, P. Flavonoid binding to human serum albumin. Biochem. Biophys. Res. Commun., 2010, 398(3), 444-449.
[http://dx.doi.org/10.1016/j.bbrc.2010.06.096] [PMID: 20599706]
[102]
Yousefi, R.; Taheri-Kafrani, A.; Nabavizadeh, S.M.; Pouryasin, Z.; Shahsavani, M.B.; Khoshaman, K.; Rashidi, M. The binding assessment with human serum albumin of novel six-coordinate Pt(IV) complexes, containing bidentate nitrogen donor/methyl ligands. Mol. Biol. Res. Commun., 2015, 4(4), 167-179.
[PMID: 27844009]
[103]
Carter, D.C.; Ho, J.X. Structure of serum albumin. Adv. Protein Chem., 1994, 45, 153-203.
[http://dx.doi.org/10.1016/S0065-3233(08)60640-3] [PMID: 8154369]
[104]
Margarson, M.P.; Soni, N. Serum albumin: Touchstone or totem? Anaesthesia, 1998, 53(8), 789-803.
[http://dx.doi.org/10.1046/j.1365-2044.1998.00438.x] [PMID: 9797524]
[105]
Fasano, M.; Curry, S.; Terreno, E.; Galliano, M.; Fanali, G.; Narciso, P.; Notari, S.; Ascenzi, P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life, 2005, 57(12), 787-796.
[http://dx.doi.org/10.1080/15216540500404093] [PMID: 16393781]
[106]
Ouameur, A.A.; Diamantoglou, S.; Sedaghat-Herati, M.R.; Nafisi, S.; Carpentier, R.; Tajmir-Riahi, H.A. The effects of drug complexation on the stability and conformation of human serum albumin: protein unfolding. Biochem. Biophysics, 2006, 45, 203-213.
[107]
Pinto, A.L.; Lippard, S.J. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta, 1985, 780(3), 167-180.
[PMID: 3896310]
[108]
van der Veer, J.L.; Peters, A.R.; Reedijk, J.; Reedijk, J. Reaction products from platinum(IV) amine compounds and 5′-GMP are mainly bis(5′-GMP)platinum(II) amine adducts. J. Inorg. Biochem., 1986, 26(2), 137-142.
[http://dx.doi.org/10.1016/0162-0134(86)80006-X] [PMID: 3007668]
[109]
Casini, A.; Reedijk, J. Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry? J. J. Chem. Sci., 2012, 3, 3135-3144.
[http://dx.doi.org/10.1039/c2sc20627g]
[110]
Mezencev, R. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: The complex world of the platinum complex. Curr. Cancer Drug Targets, 2015, 14(9), 794-816.
[http://dx.doi.org/10.2174/1568009614666141128105146] [PMID: 25431081]
[111]
Osborn, M.F.; White, J.D.; Haley, M.M.; DeRose, V.J. Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping. ACS Chem. Biol., 2014, 9(10), 2404-2411.
[http://dx.doi.org/10.1021/cb500395z] [PMID: 25055168]
[112]
Roat, R.M.; Reedijk, J.J. Reaction of mer-trichloro (diethy-lenetriamine)platmum(IV) chloride, (mer-[Pt(dien)Cl3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes. Inorg. Biochem., 1993, 52, 263-274.
[113]
Eastman, A. Chemistry and Biochemistry of a Leading Anti-cancer Drug; Wiley-VCH: New York, 2009, pp. 89-227.
[114]
Rotondo, E.; Fimiani, V.; Cavallaro, A.; Ainis, T. Does the antitumoral activity of platinum (IV) derivatives result from their in vivo reduction? Tumori, 1983, 69(1), 31-36.
[http://dx.doi.org/10.1177/030089168306900105] [PMID: 6836747]
[115]
Rosenberg, B. Some biological effects of platinum compounds. Platin. Met. Rev., 1971, 15, 42-51.
[116]
Harder, H.C. Renaturation effects of cis and trans platinum II and IV compounds on calf thymus deoxyribonucleic acid. Chem. Biol. Interact., 1975, 10(1), 27-39.
[http://dx.doi.org/10.1016/0009-2797(75)90044-7] [PMID: 234801]
[117]
Schilder, R.J.; LaCreta, F.P.; Perez, R.P.; Johnson, S.W.; Brennan, J.M.; Rogatko, A.; Nash, S.; McAleer, C.; Hamilton, T.C.; Roby, D. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res., 1994, 54(3), 709-717.
[PMID: 8306332]
[118]
Storr, T. Ligand design in medicinal inorganic chemistry; John Wiley & Sons: Chichester, 2014, pp. 9-36.
[http://dx.doi.org/10.1002/9781118697191]
[119]
Brandon, R.J.; Dabrowiak, J.C. Synthesis, characterization, and properties of a group of platinum (IV) complexes. J. Med. Chem., 1984, 27(7), 861-865.
[http://dx.doi.org/10.1021/jm00373a009] [PMID: 6330359]
[120]
Rosenberg, B. Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy. Sci. Nat., 1973, 60, 399.
[http://dx.doi.org/10.1007/BF00623551]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 6
Year: 2020
Published on: 01 October, 2020
Page: [726 - 737]
Pages: 12
DOI: 10.2174/1573407215666190409105351
Price: $65

Article Metrics

PDF: 22
HTML: 4
PRC: 1